Patents by Inventor William J. LaRochelle
William J. LaRochelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180043014Abstract: The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.Type: ApplicationFiled: June 20, 2017Publication date: February 15, 2018Inventors: Michael E. Jeffers, William J. LaRochelle
-
Publication number: 20170267750Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: March 22, 2017Publication date: September 21, 2017Inventors: Kam Fai Tse, Vincent A. Pollack, John MacDougall, Suresh G. Shenoy, Traci Mansfield, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle
-
Publication number: 20160311919Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.Type: ApplicationFiled: February 25, 2016Publication date: October 27, 2016Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
-
Publication number: 20150044212Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
-
Publication number: 20140314780Abstract: The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.Type: ApplicationFiled: July 1, 2014Publication date: October 23, 2014Inventors: Michael E. Jeffers, William J. LaRochelle
-
Publication number: 20080287349Abstract: The present invention relates to compositions and methods for preventing and treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases). More particularly, the present invention provides methods for preventing and/or treating a disease (e.g., a joint disease, ischemic stroke, hemorrhagic stroke, trauma, spinal cord damage, heavy metal or toxin poisoning, or neurodegenerative diseases) by using compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof.Type: ApplicationFiled: November 3, 2004Publication date: November 20, 2008Inventors: Jeffrey Peterson, Paul Sciore, Erik Gunther, Marie Ruiz-Martinez, Galina Chernaya, William J. LaRochelle, Michael E. Jeffers, Henri Lichenstein, Peter Mezes
-
Patent number: 7253266Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.Type: GrantFiled: June 17, 2002Date of Patent: August 7, 2007Assignee: CuraGen CorporationInventors: Richard A. Shimkets, Michael Jeffers, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein, Linda Gorman, Mei Zhong, Muralidhara Padigaru, Carol E. A. Pena, John P. Alsobrook, II, Denise M. Lepley, Daniel K. Rieger, William Grosse
-
Patent number: 7189693Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.Type: GrantFiled: December 16, 2002Date of Patent: March 13, 2007Assignee: CuraGen CorporationInventors: Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein
-
Patent number: 7056885Abstract: The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for the FGF-CX polypeptide, polynucleotide and antibody.Type: GrantFiled: July 3, 2000Date of Patent: June 6, 2006Assignee: CuraGen CorporationInventors: Michael Jeffers, Richard A. Shimkets, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein
-
Patent number: 6863889Abstract: The present invention provides novel isolated SECX polynucleotides and the membrane-associated or selected polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provide methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: September 19, 2001Date of Patent: March 8, 2005Assignee: CuraGen CorporationInventors: Richard A. Shimkets, William J. LaRochelle
-
Publication number: 20040214759Abstract: In methods of using a fibroblast growth factor, such as for treating, preventing or delaying a proliferation-associated disorder, steps are provided to administer to a subject a therapeutically effective amount of a particular fibroblast growth factor polypeptide, or variant or fragment thereof.Type: ApplicationFiled: May 9, 2003Publication date: October 28, 2004Inventors: John P. Alsobrook, Enrique Alvarez, David W. Anderson, Joel S. Bader, Ferenc L. Boldog, Catherine E. Burgess, Rajeev A. Chillakuru, Lisa Deegler, Shlomit R. Edinger, Elma R. Fernandes, Linda Gorman, William M. Grosse, John L. Herrmann, Michael E. Jeffers, William J. LaRochelle, Denise M. Lepley, Henri S. Lichenstein, Kumar Namdev, Muralidhara Padigaru, Carol E. A. Pena, Sudhirdas K. Prayaga, Daniel K. Rieger, Richard A. Shimkets, Pascal Valax, Meijia Yang, Zachary Yim, Mei Zhong
-
Publication number: 20040141969Abstract: Embodiments of the invention described herein relate to antibodies directed to platelet derived growth factor-DD (PDGF-DD) and uses of such antibodies. The antibodies of the invention find use as diagnostics and as treatments for diseases associated with the overproduction of PDGF-DD. In particular, in accordance with embodiments of the invention, the use of anti-PDGF-DD antibodies for the treatment of nephritis and related disorders, including diseases caused by mesangial proliferation is provided.Type: ApplicationFiled: September 16, 2003Publication date: July 22, 2004Inventors: Juergen Floege, Gadi Gazit-Bornstein, Bruce A. Keyt, William J. LaRochelle, Henri Stephen Lichenstein
-
Publication number: 20040067490Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: ApplicationFiled: September 6, 2002Publication date: April 8, 2004Inventors: Mei Zhong, Li Li, Linda Gorman, Kimberly A. Spytek, Ramesh Kekuda, Raymond J. Taupier, David W. Anderson, Corine A.M. Vernet, Elina Catterton, Charles E. Miller, Suresh G. Shenoy, Meera Patturajan, Carol E. A. Pena, Velizar T. Tchernev, Muralidhara Padigaru, Vladimir Y. Gusev, Uriel M. Malyankar, Catherine E. Burgess, Valerie Gerlach, Stacie J. Casman, Daniel K. Rieger, William M. Grosse, Glennda Smithson, John A. Peyman, Gary Starling, Mark E. Rothenberg, William J. LaRochelle, Richard A. Shimkets, Julie Crabtree, Luca Rastelli, Edward Z. Voss, Ferenc L. Boldog, Shlomit R. Edinger, Isabelle Millet, John R. MacDougall, Karen Ellerman, Andrei Chapoval
-
Publication number: 20040058338Abstract: The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: ApplicationFiled: December 2, 2002Publication date: March 25, 2004Inventors: Michele L. Agee, John P. Alsobrook, David W. Anderson, Constance Berghs, Ferenc L. Boldog, Catherine E. Burgess, Elina Catterton, Vincent A. DiPippo, Shlomit R. Edinger, Andrew Eisen, Karen Ellerman, Esha A. Gangolli, Valerie Gerlach, Linda Gorman, Bonnie Gould Rothberg, Xiaojia Sasha Guo, John L. Herrmann, Yuan-Di Halvorsen, Weizhen Ji, Ramesh Kekuda, Nikolai V. Khramtsov, William J. LaRochelle, Denise M. Lepley, Li Li, John R. MacDougall, Charles E. Miller, Tatiana Ort, Muralidhara Padigaru, Meera Patturajan, Carol E. A. Pena, John A. Peyman, Daniel K. Rieger, Mark E. Rothenberg, Suresh G. Shenoy, Glennda Smithson, Steven K. Spaderna, Kimberly A. Spytek, David J. Stone, Raymond J. Taupier, Corine A.M. Vernet, Edward Z. Voss, Mei Zhong
-
Publication number: 20040018199Abstract: In methods of using an ephrin receptor, such as for treating, preventing or delaying a proliferation-associated disorder such as cancer, steps are provided to administer to a subject a therapeutically effective amount of an antibody directed to an ephrin receptor polypeptide, variant or fragment thereof.Type: ApplicationFiled: May 29, 2003Publication date: January 29, 2004Inventors: Raj Bandaru, Amitabha Chaudhuri, Katherine Fries, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Uriel M. Malyankar, Chean Eng Ooi, Sudhirdas K. Prayaga, Raymond J. Taupier
-
Publication number: 20040018977Abstract: The proteins of the invention are a family used to modulate the activity of cells and their ability to attract blood vessels. The proteins are used to inhibit angiogenesis, inhibit cell migration, and inhibit actin filament formation. These proteins are used in this context to diagnose and treat proliferative disorders such as cancer.Type: ApplicationFiled: May 30, 2003Publication date: January 29, 2004Inventors: Enrique Alvarez, David W. Anderson, Mohanraj Dhanabal, Nikolai V. Khramtsov, William J. LaRochelle, Henri S. Lichenstein, Li Li, Chean Eng Ooi, Muralidhara Padigaru, Richard A. Shimkets, Mei Zhong
-
Publication number: 20040006015Abstract: The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.Type: ApplicationFiled: December 16, 2002Publication date: January 8, 2004Inventors: Ferenc L. Boldog, Catherine E. Burgess, Elma R. Fernandes, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Jeffrey Peterson, Sudhirdas K. Prayaga, Beth Rittman, Juliette B. Shimkets, Richard A. Shimkets, Meijia Yang
-
Publication number: 20040002120Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: ApplicationFiled: March 7, 2002Publication date: January 1, 2004Inventors: Ramesh Kekuda, Velizar T. Tchernev, Xiaohong Liu, Kimberly A. Spytek, Meera Patturajan, Catherine E. Burgess, Corine A.M. Vernet, Li Li, Linda Gorman, Uriel M. Malyankar, Ferenc L. Boldog, Xiaojia (Sasha) Guo, Suresh G. Shenoy, Muralidhara Padigaru, Raymond J. Taupier, Charles E. Miller, Stacie J. Casman, Carol E. A. Pena, Esha A. Gangolli, Vladimir Y. Gusev, Glennda Smithson, Bryan D. Zerhusen, Valerie Gerlach, Pascale F-J Pochart, Elma R. Fernandes, Richard A. Shimkets, Luca Rastelli, Steven K. Spaderna, William J. LaRochelle, Mei Zhong, Nikolai V. Khramtsov, Edward Z. Voss, John L. Herrmann
-
Publication number: 20030224991Abstract: Novel anti-angiogenesis proteins and the nucleic acid sequences which encode them are disclosed by the present invention.Type: ApplicationFiled: March 11, 2003Publication date: December 4, 2003Inventors: Mohanraj Dhanabal, Frank Wu, William J. LaRochelle, Henri S. Lichenstein
-
Publication number: 20030186433Abstract: The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.Type: ApplicationFiled: June 17, 2002Publication date: October 2, 2003Inventors: Richard A. Shimkets, Michael Jeffers, Sudhirdas K. Prayaga, Ferenc L. Boldog, Meijia Yang, Catherine Burgess, Elma Fernandes, John L. Herrmann, William J. LaRochelle, Henri Lichenstein, Linda Gorman, Mei Zhong, Muralidhara Padigaru, Carol E. A. Pena, John P. Alsobrook, Denise M. Lepley, Daniel K. Rieger, William Grosse